Follistatin 344 vs Myostatin Propeptide

Binds and neutralizes myostatin (GDF-8) and activin; removes the natural brake on muscle growth allowing supraphysiological hypertrophy

Follistatin-344 is the predominant endogenous isoform of follistatin, a glycoprotein that binds and neutralizes the TGF-β superfamily members activin A and myostatin, preventing their engagement with skeletal muscle ActRII receptors and thereby relieving their inhibitory effects on muscle protein synthesis and satellite cell activation. By sequestering both myostatin and activin A simultaneously, follistatin-344 neutralizes two complementary negative regulators of muscle growth through a dual-pathway mechanism, a property that distinguishes it from agents that target only the myostatin pathway. Transgenic expression of human follistatin-344 has produced significant skeletal muscle mass increases in animal models, and a phase 1/2a gene therapy trial delivering the follistatin-344 gene via AAV to patients with Becker muscular dystrophy established initial proof of concept and safety data in a human clinical context. Follistatin-344 has not received FDA approval for any indication; exogenous administration as a recombinant protein or peptide is investigational and no human safety data exists for this route of administration outside gene therapy trial contexts. Follistatin-344 as a research compound: recombinant follistatin-344 protein is available through research biochemical suppliers as a laboratory reagent, used in cell culture and animal models to probe myostatin and activin A biology. Interest in exogenous follistatin-344 administration in performance contexts has grown from the animal model hypertrophy data; however, the protein's large molecular weight (~35 kDa glycoprotein) creates significant bioavailability challenges for subcutaneous or intramuscular routes, and no human pharmacokinetic data supports assumed tissue distribution from injection. This distinguishes it from smaller peptide-based myostatin modulators. Follistatin-344 vs myostatin propeptide: both target myostatin inhibition but through different binding mechanisms. Follistatin-344 binds activin A in addition to myostatin, providing a broader TGF-β inhibition profile. Myostatin propeptide is the endogenous inhibitory domain of the myostatin precursor protein — it is myostatin-specific but structurally derived from the same protein rather than from a binding antagonist class. Both compounds remain at the research stage for performance applications with no approved human use. Providers offering research peptides in the performance and muscle recovery category are listed in the PeptideBase directory.

Endogenous N-terminal fragment of myostatin precursor; binds and neutralizes mature myostatin (GDF-8); naturally produced to regulate the extent of muscle inhibition

Myostatin propeptide is the endogenous N-terminal prodomain of the precursor myostatin protein (GDF-8) that, following cleavage of the mature myostatin dimer, remains non-covalently associated with it as a latency-associated complex, maintaining the active growth factor in an inactive state until proteolytic activation by BMP-1/tolloid family metalloproteinases releases it to engage ActRIIB receptors and signal through the Smad2/3 pathway. Recombinant versions of the propeptide can act as endogenous-mechanism inhibitors of myostatin by sequestering the mature peptide in an inactive complex, reducing the inhibitory signaling that myostatin exerts on skeletal muscle protein synthesis and satellite cell activity in the ActRII/Smad pathway. Foundational rodent studies demonstrate that overexpression of the myostatin propeptide produces significant skeletal muscle hypertrophy, and the BMP-1/tolloid proteolytic activation mechanism of the propeptide-myostatin latent complex has been characterized genetically in mouse models. Myostatin propeptide is a research compound with no regulatory approval in any jurisdiction; recombinant propeptide administration has not been evaluated in human clinical trials for muscle building or performance applications, and no human safety or pharmacokinetic data has been established.